Scotland follows NICE with no to Novartis's Afinitor and Celgene's Vidaza
This article was originally published in Scrip
The Scottish Medicines Consortium, Scotland's health technology appraisal body, said on 12 April that it would not be recommending Novartis's Afinitor (everolimus) for the treatment of advanced renal cell carcinoma (RCC) or Celgene's Vidaza (azacitidine) for the treatment of myelodysplastic syndrome, chronic myelomonocytic leukaemia and acute myeloid leukaemia on the Scottish NHS.
You may also be interested in...
A Dutch parallel registration and reimbursement pilot has brought benefits including more participation from healthcare professionals, and also forces company divisions to be less streamlined.
The UK’s withdrawal from the EU could upset the Unitary Patent Court project.
International reference pricing has created narrow price corridors that can limit access to medicines and vaccines in lower income countries. The issue will start to impact higher income EU markets if US plans to introduce IRP come to fruition.